Riera, P, Paez, D. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opinion on Drug Metabolism & Toxicology. 2021; 17(10)DOI:10.1080/17425255.2021.1974397. PMID:34486919. IF:4.936(Q1/3D).

Herbst, RS, Garon, EB, Kim, DW, Cho, BC, Gervais, R, Perez-Gracia, JL, Han, JY, Majem, M, Forster, MD, Monnet, I, Novello, S, Gubens, MA, Boyer, M, Su, WC, Samkari, A, Jensen, EH, Kobie, J, Piperdi, B, Baas, P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. Research in Social & Administrative Pharmacy. 2021; 16(10)DOI:10.1016/j.jtho.2021.05.001. PMID:34048946. IF:3.348(Q2/5D).

Ribelles, N, Alvarez-Lopez, I, Arcusa, A, Chacon, JI, de la Haba, J, Garcia-Corbacho, J, Garcia-Mata, J, Jara, C, Jerez, JM, Lazaro-Quintela, M, Leon-Mateos, L, Ramirez-Merino, N, Tibau, A, Garcia-Palomo, A. Electronic health records and patient registries in medical oncology departments in Spain. Clinical & Translational Oncology. 2021; 23(10)DOI:10.1007/s12094-021-02614-9. PMID:33864619. IF:3.340(Q3/7D).

Riudavets, M, Sullivan, I, Abdayem, P, Planchard, D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021; 6(5)DOI:10.1016/j.esmoop.2021.100260. PMID:34479034. IF:6.883(Q1/3D).

Blackhall, F, Jao, K, Greillier, L, Cho, BC, Penkov, K, Reguart, N, Majem, M, Nackaerts, K, Syrigos, K, Hansen, K, Schuette, W, Cetnar, J, Cappuzzo, F, Okamoto, I, Erman, M, Langer, SW, Kato, T, Groen, H, Sun, ZW, Luo, Y, Tanwani, P, Caffrey, L, Komarnitsky, P, Reinmuth, N. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology. 2021; 16(9)DOI:10.1016/j.jtho.2021.02.009. PMID:33607312. IF:20.121(Q1/1D).

Garrido, P, Paz-Ares, L, Majem, M, Moran, T, Trigo, JM, Bosch-Barrera, J, Garcia-Campelo, R, Gonzalez-Larriba, JL, Sanchez-Torres, JM, Isla, D, Vinolas, N, Camps, C, Insa, A, Juan, O, Massuti, B, Paredes, A, Artal, A, Lopez-Brea, M, Palacios, J, Felip, E. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 2021; 10(17)DOI:10.1002/cam4.4135. PMID:34296539. IF:4.711(Q2/5D).

Vokinger, KN, Hwang, TJ, Daniore, P, Lee, CC, Tibau, A, Grischott, T, Rosemann, TJ, Kesselheim, AS. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncology. 2021; 7(9)DOI:10.1001/jamaoncol.2021.2026. PMID:34196656. IF:33.012(Q1/1D).

Moreno, V, Greil, R, Yachnin, J, Majem, M, Wermke, M, Arkenau, HT, Basque, JR, Nidamarthy, PK, Kapoor, S, Cui, XM, Giovannini, M. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. CLINICAL THERAPEUTICS. 2021; 43(6)DOI:10.1016/j.clinthera.2021.04.006. PMID:34053700. IF:3.637(Q2/5D).